Compositions of matter and pharmaceutical compositions
Inventors
WITOWSKI, CHRISTOPHER G. • Salm, Jacqueline L.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11759452-B2
Publication Date
2023-09-19
Expiration Date
Abstract
Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.
Core Innovation
The patent describes novel indole compounds defined by the formula of Structure (1), including substituents where X is CF3 or a halogen selected from Cl, Br, I, and astatine. The compounds include an aliphatic substituent R1 containing a primary, secondary, tertiary, or quaternary amine, and R2 selected from hydroxyl, an ester, an ether, an aldehyde, an acid, an amide, a thiol, a sulfone, a sulfonamide, or combinations thereof.
The patent further describes psilocybin and psilocybin-analogue actives associated with indole compound structures. Pharmaceutical compositions are disclosed for systemic delivery including transdermal, nasal, and oral routes, and the document specifies formulations corresponding to these routes.
The document also provides documented characterization of indole-based transdermal delivery, including a DMT transdermal patch formulation and associated release and delivery performance metrics. It also includes additional intranasal gel formulation discussion and computational support for receptor interactions, including virtual docking referencing 5-HT receptors and sigma-1.
Claims Coverage
The provided claim set includes two independent claims directed to compound structures of Structure (1), each specifying core substituent definitions for X, R1, and R2. The inventive features are centered on the structure-defining substituent pattern of the indole compounds and, in one claim family, fixing X to Br.
Indole compound with Structure (1) substituent pattern
A compound of the formula of Structure (1) wherein X is CF3, or a halogen selected from Cl, Br, I, and astatine; R1 consists of an aliphatic substituent with a primary, secondary, tertiary, or quaternary amine; and R2 is hydroxyl, an ester, an ether, an aldehyde, an acid, an amide, a thiol, a sulfone, a sulfonamide or combinations thereof.
Indole compound with Structure (1) and X fixed to Br
A compound of the formula of Structure (1) wherein X is Br; R1 consists of an aliphatic substituent with a primary, secondary, tertiary, or quaternary amine; and R2 is hydroxyl, an ester, an ether, an aldehyde, an acid, an amide, a thiol, a sulfone, a sulfonamide or combinations thereof.
The independent claims define indole compounds by the Structure (1) framework, with inventive features focused on the allowed values for X, the amine-containing aliphatic R1, and the functional-group R2 selection.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Transdermal systemic delivery, including transdermal patch formulations.
Nasal systemic delivery, including nasal gel formulations.
Oral systemic delivery, including oral tablets, capsules, and films.
Therapeutic targeting for neurological, mood, and abuse disorders, including combinations with MAOIs and/or 5-HT antagonists.
Interested in licensing this patent?